Ajanta Pharma announced a 20% increase in Profit After Tax (PAT) for Q2 FY26. The company reported a revenue increase of 14%, reaching ₹1,354 cr. The Board approved an interim dividend of ₹28 per share. These results showcase strong performance in branded generics, particularly within the Indian market. The company’s strategic focus on chronic therapies and operational efficiencies drives sustained growth.
Financial Performance Highlights
Ajanta Pharma reported a strong financial performance for Q2 FY26, marked by significant growth in key metrics:
- Revenue from Operations: Increased by 14% to ₹1,354 cr, compared to ₹1,187 cr in Q2 FY25.
- EBITDA: Rose to ₹328 cr, a 5% increase from ₹311 cr in Q2 FY25.
- Profit After Tax (PAT): Grew by 20% to ₹260 cr, up from ₹216 cr in Q2 FY25.
Excluding mark-to-market forex losses, EBITDA would stand at ₹369 cr with a margin of 27%, and PAT would grow by 23% with a margin of 22%.
Interim Dividend Announcement
The Board of Directors has approved an interim dividend of ₹28 per share, amounting to approximately ₹350 cr.
H1 FY26 Performance Overview
The company sustained its growth momentum in the first half of FY26:
- Revenue from Operations: Increased by 14% to ₹2,656 cr, from ₹2,332 cr in H1 FY25.
- EBITDA: Increased by 6% to ₹679 cr.
- Profit After Tax (PAT): Increased by 12% to ₹516 cr.
Excluding mark-to-market forex losses, EBITDA would stand at ₹745 cr, reflecting a margin of 28%.
Segment Performance
Branded Generics: Saw growth across key markets:
- India: Increased by 12%, from ₹386 cr to ₹432 cr.
- Asia: Increased by 5%, from ₹296 cr to ₹310 cr.
- Africa: Increased by 4%, from ₹213 cr to ₹221 cr.
US Generics: Experienced substantial growth, up 48% from ₹232 cr to ₹344 cr.
Operational Highlights
- India branded generic performance exceeded IPM growth by 32%, driven by volume increases and new launches.
- Strong focus on chronic therapies, with 65% of sales coming from this segment.
- R&D expenses remain consistent at 5% of revenue.
Source: BSE
